Newsroom

Sorted by: Latest

-

Renee Russo named Exit Planner of the Year at 2026 Exit Planning Summit

CLEVELAND--(BUSINESS WIRE)--Exit Planning Institute® (EPI) announced today the winners of the annual Excellence in Exit Planning Awards....
-

QXO to Acquire TopBuild for $17 Billion

GREENWICH, Conn. & DAYTONA BEACH, Fla.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced that it has entered into a definitive agreement to acquire TopBuild Corp. (NYSE: BLD) (“TopBuild”) for approximately $17 billion, significantly expanding QXO’s scale and capabilities across the building products value chain. The transaction is expected to be immediately and substantially accretive to the company’s earnings. TopBuild is the largest distributor and installer of insulation and related bu...
-

Block Blast! Brings Its Brand to Coachella as Visibility Grows in the U.S.

LOS ANGELES--(BUSINESS WIRE)--On April 17, Block Blast! appeared at Coachella through a branded ad truck and aerial banner activation. ...
-

Impact Capital Group Releases New Analysis on Real Estate’s Growing Influence on Lower Middle Market M&A Transaction Outcomes

LOS ANGELES--(BUSINESS WIRE)--Impact Capital Group, Inc. (“Impact”), a lower middle market investment banking and valuation firm, today announced the release of a new analysis examining how owned and leased real estate can materially influence private company sale transactions. The analysis, titled “The Real Estate Variable: How Real Estate Shapes, Complicates, and Sometimes Derails Lower Middle Market M&A,” draws on anonymized case studies from Impact’s advisory experience and highlights t...
-

Lundbeck Presents New Data at AAN 2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (eptinezumab-jjmr)

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI...
-

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...
-

HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications

PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic potential is extending to a range of conditions including cardiovascular and neurodegenerative...
-

Inocras and Broad Institute Researchers Present New TCGA Whole-Genome Cancer Insights, Accelerating Discovery in Cancer Genomics

SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer wh...
-

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h...
-

Rosen Law Firm Encourages Green Circle Decarbonize Technology Ltd. Investors to Inquire About Securities Class Action Investigation – GCDT

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Green Circle Decarbonize Technology Ltd. (NYSE American: GCDT) resulting from allegations that Green Circle may have issued materially misleading business information to the investing public. So what: If you purchased Green Circle securities you may be entitled to compensation without payment of any out of pocket fees or costs...